BioXcel Therapeutics, Inc. (BTAI)

Innovative Medicine Backed by the Power of Artificial Intelligence

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology.

About Us

Company’s Approach to Drug Development

AI-based Drug Development

Our neuroscience and immuno-oncology programs utilize our AI approach to drug development.

BXCL501

BXCL501 is an investigational, proprietary, orally dissolving, thin film formulation of dexmedetomidine designed for the treatment of agitation and opioid withdrawal symptoms.

BXCL701

BXCL701 is an investigational, orally-administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Latest News

May 4, 2021 7:00 AM EDT

BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

View Release

May 3, 2021 7:00 AM EDT

BioXcel Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast

View Release

Apr 29, 2021 7:00 AM EDT

BioXcel Therapeutics Launches “Boiling Point” Educational Campaign to Shed Light on the Importance of Prompt and Cooperative De-escalation in the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

View Release

View all news

Stock Information